Anika Therapeutics (ANIK) Leases: 2011-2025
Historic Leases for Anika Therapeutics (ANIK) over the last 7 years, with Sep 2025 value amounting to $24.2 million.
- Anika Therapeutics' Leases fell 10.96% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year decrease of 10.96%. This contributed to the annual value of $25.7 million for FY2024, which is 6.78% down from last year.
- Anika Therapeutics' Leases amounted to $24.2 million in Q3 2025, which was down 2.01% from $24.7 million recorded in Q2 2025.
- In the past 5 years, Anika Therapeutics' Leases ranged from a high of $31.6 million in Q2 2022 and a low of $20.5 million during Q1 2022.
- Over the past 3 years, Anika Therapeutics' median Leases value was $27.6 million (recorded in 2023), while the average stood at $27.2 million.
- In the last 5 years, Anika Therapeutics' Leases soared by 47.07% in 2023 and then fell by 10.96% in 2025.
- Quarterly analysis of 5 years shows Anika Therapeutics' Leases stood at $21.0 million in 2021, then soared by 46.47% to $30.7 million in 2022, then fell by 10.24% to $27.6 million in 2023, then dropped by 6.78% to $25.7 million in 2024, then fell by 10.96% to $24.2 million in 2025.
- Its Leases was $24.2 million in Q3 2025, compared to $24.7 million in Q2 2025 and $25.2 million in Q1 2025.